

1 TO THE HOUSE OF REPRESENTATIVES:

2 The Committee on Human Services to which was referred Senate Bill No.
3 114 entitled “An act relating to the establishment of the Psychedelic Therapy
4 Advisory Working Group” respectfully reports that it has considered the same
5 and recommends that the House propose to the Senate that the bill be amended
6 by striking out all after the enacting clause and inserting in lieu thereof the
7 following:

8 Sec. 1. PSYCHEDELIC THERAPY ADVISORY WORKING GROUP;
9 STUDY

10 (a) Creation. There is created the Psychedelic Therapy Advisory Working
11 Group for the purpose of reviewing existing research on the cost-benefit profile
12 of the use of psychedelics to improve mental health and to make findings and
13 recommendations regarding the advisability of the establishment of a State
14 program to permit health care providers to administer psychedelics in a
15 therapeutic setting and the impact on public health of allowing individuals to
16 legally access psychedelics under State law.

17 (b) Membership. The Working Group shall be composed of the following
18 members:

19 (1) the Dean of the Larner College of Medicine at the University of
20 Vermont or designee;

21 (2) the President of the Vermont Psychological Association or designee;

1 (3) the President of the Vermont Psychiatric Association or designee;

2 (4) the Executive Director of the Vermont Board of Medical Practice or
3 designee;

4 (5) the Director of the Vermont Office of Professional Regulation or
5 designee;

6 (6) the Executive Director of the Vermont Medical Society or designee;

7 (7) the Vermont Commissioner of Health or designee; and

8 (8) the Vermont Commissioner of Mental Health or designee.

9 (c) Powers and duties.

10 (1) The Working Group shall:

11 (A) review the latest research and evidence of the public health
12 benefits and risks of clinical psychedelic assisted treatments; and

13 (B) examine the laws and programs of other states that have
14 authorized the use of psychedelics by health care providers in a therapeutic
15 setting and necessary components and resources if Vermont were to pursue
16 such a program.

17 (2) The Working Group shall seek testimony from Johns Hopkins’
18 Center for Psychedelic and Consciousness Research, in addition to any other
19 entities with an expertise in psychedelics.

20 (d) Assistance. The Working Group shall have the assistance of the
21 Vermont Department of Mental Health for purposes of scheduling and staffing

1 meetings and developing and submitting the report required by subsection (e)
2 of this section.

3 (e) Report. On or before November 15, 2024, the Working Group shall
4 submit a written report to the House and Senate Committees on Judiciary, the
5 House Committee on Health Care, the House Committee on Human Services,
6 and the Senate Committee on Health and Welfare with its findings and any
7 recommendations for legislative action.

8 (f) Meetings.

9 (1) The Vermont Department of Mental Health shall call the first
10 meeting of the Working Group to occur on or before July 15, 2024.

11 (2) The Working Group shall select a chair from among its members at
12 the first meeting.

13 (3) A majority of the membership shall constitute a quorum.

14 (4) The Working Group shall cease to exist on January 1, 2025.

15 Sec. 2. EFFECTIVE DATE

16 This act shall take effect on July 1, 2024.

17

18

19

20

21

1

2

3 (Committee vote: _____)

4

5

Representative _____

6

FOR THE COMMITTEE